TG-6002-derived vaccinia virus (Transgene)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameTG-6002-derived vaccinia virus (Transgene)
Drug Alias Nameoncolytic vaccinia virus therapy expressing FCU1 and an intrabody (Transgene)
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTransgene Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTransgene Sa
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A